"New Drug Offers Hope for Non-Obese Sleep Apnea Patients"
A new drug, AD109, developed by Apnimed, could potentially replace CPAP machines for treating sleep apnea, offering a less cumbersome and more cost-effective solution. The drug, a combination of aroxybutynin and atomoxetine, has shown promising results in phase II trials, particularly for mild cases of obstructive sleep apnea (OSA), with no major side effects reported. However, concerns remain about its efficacy for severe cases and the absence of oxygen saturation data in the trials. A third trial is currently underway.